Dr Jin San-Yoo, president and CEO of PharmAbcine, lifts the lid on the company’s combination therapy with MSD’s blockbuster oncology treatment Keytruda. Dr Yoo explains the rationale behind his decision to base his clinical trials in Australia and provides his assessment of the future for oncology drug development in the global market.
I am very excited about this clinical collaboration with Merck (MSD)’s team. We are learning and experiencing enormously from their experience. The Merck team are very supportive and considerate, so I am very grateful for the opportunity.
